[Relationship between p53 rs1625895 polymorphism and prognosis in diffuse large B-cell lymphoma]

Area of Science:

• Oncology
• Genetics
• Hematology

Background:

• The p53 gene, known as "the guardian of the genome", is a crucial tumor suppressor gene frequently altered in various cancers.
• Approximately 50% of all tumors exhibit p53 dysfunction, highlighting its significance in cancer development and progression.
• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with heterogeneous clinical outcomes.

Purpose of the Study:

• To investigate the association between the p53 rs1625895 polymorphism and the prognosis of patients diagnosed with DLBCL.
• To determine if this specific p53 polymorphism influences clinical characteristics, treatment response, and survival rates in DLBCL patients.

Main Methods:

• A cohort of 384 DLBCL patients was analyzed retrospectively.
• Polymerase Chain Reaction (PCR) combined with Sanger sequencing was employed to determine the rs1625895 genotype.
• Statistical analyses were performed to correlate genotypes with clinical features, treatment efficacy, and patient survival.

Main Results:

• The study identified GG genotype in 90.6% of patients, AG in 8.9%, and AA in 0.5%.
• No significant differences were observed in clinical characteristics, overall response rates (ORR), or survival between different rs1625895 genotypes in the overall DLBCL cohort.
• However, in the Germinal Center B-cell (GCB) subtype, A allele carriers showed significantly longer progression-free survival (PFS) and overall survival (OS) compared to GG homozygotes.

Conclusions:

• The p53 rs1625895 polymorphism is not a reliable predictor of clinical efficacy or prognosis in the general DLBCL population treated with first-line chemotherapy.
• In patients with the GCB subtype of DLBCL, the p53 rs1625895 polymorphism may serve as a valuable prognostic biomarker.
• Further research is warranted to elucidate the precise role of p53 polymorphisms in DLBCL subtypes and treatment strategies.